Test Page

Arun Sengupta has over 30 years experience working in the financial markets, private equity and corporate finance sector.

Arun started his career in 1987 working in Treasury at Westpac Banking Corporation as a graduate trainee and was offered a permanent position in Treasury in 1988. Arun’s responsibilities involved running exchanged-traded options for both the bond and bill books for Westpac Banking Corporation. He later also ran the over-the-counter bond option book on all government and semi issued bonds.

In 1992 Arun started his own trading business. He traded futures and options on all major exchanges for the next 25 years. In 2001 he also started trading listed stocks, primarily on the Australian Stock Exchange.

In 2017 Arun became one of the founding directors of Canary Capital.

Arun joined the board of Veriluma as a director on 14th March 2018 with the sole purpose of getting the company out of administration and re-capitalised and relisted on the ASX. After achieving this objective Arun resigned on 10th September 2019.

Arun is on the advisory board for DekkoSecure, an unlisted Australian IT company, in 2016 and still serving the company in this role. Canary Capital has been working with Dekko Secure since April 2017.

Arun has participated in a broad range of corporate advisory, funds management and principal investment activities. He has been involved in the establishment, fundraising and operation of both ASX listed companies and in private equity.

Dr Chris Baldwin received his PhD in Chemical Engineering from the University of Cambridge, while matriculated at Trinity College. Chris joined Exopharm in November 2019, bringing a wide range of global commercial experience to the company.

Most recently, Chris was responsible for Haemonetics’ largest and most profitable business unit across Asia Pacific, with P&L responsibilities from Taiwan to Pakistan. Previously responsible for all sales and marketing in Southeast Asia, Chris provided strategy leadership across Asia Pacific, including China.

Chris’ strategic focus and approach to management comes from his time at McKinsey and Company, where he served banking, pharmaceutical and NGO clients.

Healthcare became the focus of Chris’ career at New York Blood Center, where he was Executive Director for 8 years and responsible for the blood supply across the greater New York metropolitan area. He founded and currently serves as Chairman of APAC Bioplasma Solutions Pte, a company that helps blood services and hospitals make productive use of their excess donations.

Christopher Cox is a Co-Founder and Managing Partner of Population Health Partners since April 2020. He is also a Senior Attorney and retired Partner at Cadwalader, Wickersham & Taft LLP, where he led the Corporate Department and served on the Management Committee. With expertise in mergers and acquisitions, restructurings, spin-offs, and complex financing, Chris was seconded from 2016 to 2019 to The Medicines Company as Executive Vice President and Chief Corporate Development Officer, overseeing business development and strategy.

Earlier in his career, he was a partner at Cahill Gordon & Reindel LLP. Currently, Chris is the CEO of Symphony Capital Holdings, LLC, a private investment firm with interests in biotechnology, network security, and entertainment.

Colin Napier has over 30 years’ experience in the accounting profession. The first 12 years a public accountant with international firms such as pwc and RSM Bird Cameron. The last 20 years have included a 5-year role as CFO of Coogee Chemicals and over 2 years as CFO of ASX listed Neptune Marine Services.

Colin has extensive practical experience in the selling and purchasing of businesses, developing Board and management reports, preparing financial reports, raising debt funding (in excess of $125M), cashflow projections and control, and capital investment analysis.

He has a Bachelor of Commerce from UWA, is a Chartered Accountant and holds an Executive MBA from the Australian Graduate School of Management.